Xigen Inflammation Ltd.
Records under this name other than the patents Xigen Inflammation Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Back to Xigen Inflammation Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,290,538 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway Term ended Term ended Sep 12, 2026 · High confidence | Term ended | Term ended Sep 12, 2026 | High confidence |
| US 10,023,615 | Efficient Transport into White Blood Cells Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 8,748,395 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway Formerly held Lapsed on the fee record Ended Jun 10, 2026 · High confidence | Lapsed on the fee record | Ended Jun 10, 2026 | High confidence |
| US 11,331,364 | Use for JNK inhibitor molecules for treatment of various diseases Lapsed on the fee record Ended May 17, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 17, 2026 | From the USPTO record |
| US 8,080,517 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway Term ended Term ended Sep 12, 2025 · High confidence | Term ended | Term ended Sep 12, 2025 | High confidence |
| US 9,624,267 | JNK inhibitor molecules Lapsed on the fee record Ended Apr 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 18, 2025 | From the USPTO record |
| US 10,967,038 | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases Lapsed on the fee record Ended Apr 6, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 6, 2025 | From the USPTO record |
| US 9,610,330 | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases Lapsed on the fee record Ended Apr 4, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 4, 2025 | From the USPTO record |
| US 8,183,339 | Cell-permeable peptide inhibitors of the JNK signal transduction pathway Lapsed on the fee record Ended May 22, 2024 · From the USPTO record | Lapsed on the fee record | Ended May 22, 2024 | From the USPTO record |
| US 10,596,223 | JNK inhibitor molecules for treatment of various diseases Lapsed on the fee record Ended Mar 24, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 24, 2024 | From the USPTO record |